Summary This blood cancer discovery highlights a new approach for investigating blood cancers and bone marrow disorders. MPNs or myeloproliferative neoplasms are blood cancers in which the bone marrow makes too many red blood cells, platelets or white blood cells. Currently, there are limited models available to understand the development and response to treatments of […]
How important is fibrosis in myelofibrosis?
by David Wallace What is fibrosis in myelofibrosis? Myelofibrosis is characterized by an accumulation of fibrous tissue (fibrosis) or scar tissue in the bone marrow. As fibrosis increases, it impairs the bone marrow’s ability to produce healthy blood cells. This can cause numerous symptoms, including anemia, fatigue, weakness and an increased risk of bleeding and […]
Is there a Connection between MPNs and Autoimmune Diseases?
by David Wallace Patients are Asking – Episode 2 of 3 In this interview with MPN expert, Dr. Angela Fleischman, we discuss the latest treatments for myelofibrosis (MF) and when a clinical trial should be considered. Research has linked MPNs to a pre-disposition to autoimmune disorders such as Lupus, Crohn’s disease and Psoriasis just to […]
What constitutes disease modification in myelofibrosis?
Abstract The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what constitutes disease modification of myelofibrosis to advance appropriate drug […]
Momelotinib: emerging treatment for myelofibrosis patients with anemia
Abstract The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the […]
- Next Page »